Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Expert Review of Anti-Infective Therapy|November 2, 2012
The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patientsSteven F L van Lelyveld, Annemarie M J Wensing, Andy I M Hoepelman
Cardiovascular Toxicology|January 2, 2021
QTc Prolongation in COVID-19 Patients Using ChloroquineMatthijs L Becker, Dominic Snijders, Claudia W van Gemeren, et al.
AIDS (London, England)|November 25, 2011
Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohortSteven F L van Lelyveld, Luuk Gras, Anouk Kesselring, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2010
Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacityAxel Fun, Kurt Van Baelen, Steven F L van Lelyveld, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 2, 2021
[Rectal lesions and liver lesions caused by syphilis]Jelle L G Haitsma Mulier, Yvette H van Beurden, Brechje C van Eijck, et al.
AIDS (London, England)|January 2, 2013
Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands host or environmental factors?Annelot F Schoffelen, Steven F L van Lelyveld, Roos E Barth, et al.
The Journal of Antimicrobial Chemotherapy|March 12, 2011
Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patientJori Symons, Steven F L van Lelyveld, Andy I M Hoepelman, et al.
The Journal of Infectious Diseases|January 21, 2015
Diminished impact of ethnicity as a risk factor for chronic kidney disease in the current HIV treatment eraAnnelot F Schoffelen, Colette Smit, Steven F L van Lelyveld, et al.
Pageof 3